Literature DB >> 20720232

Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits.

Tetsuya Sugiyama1, Maho Shibata, Sumiko Kajiura, Takashi Okuno, Masahiro Tonari, Hidehiro Oku, Tsunehiko Ikeda.   

Abstract

PURPOSE: To investigate the effects of fasudil, a Rho-associated coiled coil-forming protein kinase (ROCK) inhibitor, on normal or impaired optic nerve head (ONH) blood flow in a rabbit model.
METHODS: ONH blood flow was measured by laser speckle flowgraphy. Changes in ONH blood flow were examined during a continuous intravenous infusion of fasudil with and without the application of N(G)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor. Effects of topical fasudil on ONH blood flow were investigated in normal eyes or models of ocular circulation impairment induced by the application of endothelin (ET)-1. Visual-evoked potentials (VEPs) and morphologic and histologic changes were also analyzed in the ET-1-injected eyes.
RESULTS: A continuous intravenous infusion of fasudil had no significant effect on normal ONH blood flow, yet it prevented or improved the ONH blood flow impairment induced by the intravenous injection of L-NAME. Repeated intravitreal injections of ET-1 twice a week for 4 weeks decreased the ONH blood flow, prolonged the VEPs' implicit time, enlarged the optic cup, and decreased retinal ganglion cells. Multiple doses of topical fasudil ameliorated the ONH impairments caused by ET-1.
CONCLUSIONS: These results show that systemic or topical fasudil suppresses impairment of ONH blood flow, function, and morphology induced by L-NAME or ET-1. A ROCK inhibitor can be useful for the treatment of impaired ONH blood flow.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20720232     DOI: 10.1167/iovs.10-5265

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 2.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 3.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

4.  Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.

Authors:  Hiroshi Watabe; Sanae Abe; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2011-06-11       Impact factor: 2.447

Review 5.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

6.  Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.

Authors:  Yusuke Ohta; Sanae Takaseki; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2017-06-26       Impact factor: 2.447

Review 7.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Authors:  Kang Zhang; Liangfang Zhang; Robert N Weinreb
Journal:  Nat Rev Drug Discov       Date:  2012-06-15       Impact factor: 84.694

8.  Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.

Authors:  Peter X Shaw; Alan Sang; Yan Wang; Daisy Ho; Christopher Douglas; Lara Dia; Jeffrey L Goldberg
Journal:  Exp Eye Res       Date:  2016-07-18       Impact factor: 3.467

Review 9.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

10.  Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2019-12-24       Impact factor: 1.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.